Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart (VXRT) has announced the granting of inducement equity awards to new employees on March 24, 2025. The awards include stock options and restricted stock units (RSUs) for seven non-executive employees, totaling 292,500 shares (195,000 stock options and 97,500 RSUs). Additionally, Laurie Hastings, the new Senior Vice President of Human Resources, received 300,000 stock options and 67,000 RSUs.
The stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly. RSUs vest 25% annually over four years. These awards were granted under the Vaxart 2024 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new employees as employment inducement.
Vaxart (VXRT) ha annunciato l'assegnazione di premi azionari per incentivare i nuovi dipendenti il 24 marzo 2025. I premi includono opzioni su azioni e unità azionarie vincolate (RSU) per sette dipendenti non esecutivi, per un totale di 292.500 azioni (195.000 opzioni su azioni e 97.500 RSU). Inoltre, Laurie Hastings, la nuova Vicepresidente Senior delle Risorse Umane, ha ricevuto 300.000 opzioni su azioni e 67.000 RSU.
Le opzioni su azioni maturano nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente. Le RSU maturano annualmente del 25% per quattro anni. Questi premi sono stati concessi ai sensi del Piano di Premi di Incentivo Vaxart 2024 in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), specificamente progettato per i nuovi dipendenti come incentivo all'assunzione.
Vaxart (VXRT) ha anunciado la concesión de premios de acciones para incentivar a nuevos empleados el 24 de marzo de 2025. Los premios incluyen opciones sobre acciones y unidades de acciones restringidas (RSUs) para siete empleados no ejecutivos, totalizando 292,500 acciones (195,000 opciones sobre acciones y 97,500 RSUs). Además, Laurie Hastings, la nueva Vicepresidenta Senior de Recursos Humanos, recibió 300,000 opciones sobre acciones y 67,000 RSUs.
Las opciones sobre acciones se consolidan durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente. Las RSUs se consolidan un 25% anualmente durante cuatro años. Estos premios se otorgaron bajo el Plan de Premios de Incentivo Vaxart 2024 en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4), diseñado específicamente para nuevos empleados como incentivo de empleo.
Vaxart (VXRT)는 2025년 3월 24일에 새로운 직원들에게 유인 주식 보상을 지급한다고 발표했습니다. 이 보상에는 7명의 비임원 직원에게 총 292,500주(195,000주 옵션 및 97,500주 RSU)에 대한 주식 옵션 및 제한 주식 단위(RSU)가 포함됩니다. 또한, Laurie Hastings는 새로운 인사 부사장으로서 300,000주 옵션과 67,000주 RSU를 받았습니다.
주식 옵션은 4년에 걸쳐 분할 지급되며, 1년 후 25%가 지급되고 나머지는 매달 지급됩니다. RSU는 4년에 걸쳐 매년 25%가 지급됩니다. 이 보상은 Vaxart 2024 유인 보상 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 직원 유인을 위해 특별히 설계되었습니다.
Vaxart (VXRT) a annoncé le 24 mars 2025 l'octroi de récompenses en actions pour inciter de nouveaux employés. Les récompenses comprennent des options d'achat d'actions et des unités d'actions restreintes (RSU) pour sept employés non exécutifs, totalisant 292 500 actions (195 000 options d'achat d'actions et 97 500 RSU). De plus, Laurie Hastings, la nouvelle vice-présidente senior des ressources humaines, a reçu 300 000 options d'achat d'actions et 67 000 RSU.
Les options d'achat d'actions sont acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement. Les RSU sont acquises à raison de 25 % par an sur quatre ans. Ces récompenses ont été accordées dans le cadre du Plan de Récompenses d'Incinération Vaxart 2024 en conformité avec la règle de cotation Nasdaq 5635(c)(4), spécifiquement conçu pour les nouveaux employés comme incitation à l'embauche.
Vaxart (VXRT) hat am 24. März 2025 die Gewährung von Anreiz-Aktienoptionen an neue Mitarbeiter angekündigt. Die Auszeichnungen umfassen Aktienoptionen und eingeschränkte Aktieneinheiten (RSUs) für sieben nicht-executive Mitarbeiter, insgesamt 292.500 Aktien (195.000 Aktienoptionen und 97.500 RSUs). Zusätzlich erhielt Laurie Hastings, die neue Senior Vice President für Personalwesen, 300.000 Aktienoptionen und 67.000 RSUs.
Die Aktienoptionen werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig werden und der Rest monatlich. RSUs werden über vier Jahre jährlich um 25% fällig. Diese Auszeichnungen wurden im Rahmen des Vaxart 2024 Anreiz-Award-Plans gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt, die speziell für neue Mitarbeiter als Beschäftigungsanreiz konzipiert wurde.
- Strategic hiring and retention tool through equity compensation
- Structured vesting schedule helps ensure long-term employee retention
- Potential dilution of existing shareholders due to issuance of 659,500 new shares
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 shares and restricted stock unit awards covering 97,500 shares, and (ii) Laurie Hastings, our recently-appointed Senior Vice President, Human Resources, consisting of a stock option to purchase 300,000 shares and a restricted stock unit award covering 67,000 shares, in each case as a material inducement for those individuals to commence employment with Vaxart.
The stock options vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share exercise price equal to the closing price of Vaxart’s common stock on the grant date; and the restricted stock unit awards vest as to
These awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment “inducement award” pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Vaxart (or following a bona fide period of non-employment) as an inducement material to entering into employment with Vaxart.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
How many shares are included in Vaxart's (VXRT) March 2025 inducement equity awards?
What is the vesting schedule for VXRT's March 2025 inducement stock options?
How do the restricted stock units (RSUs) vest in Vaxart's March 2025 inducement grants?
What equity awards did Vaxart's new SVP of HR receive in March 2025?
